YU39602B - Process for the conversion of beclomethasone 17,21-di-propionate the crystals whereof are liable to growth in an aerosol propellent into a from showing no such growth tendency - Google Patents

Process for the conversion of beclomethasone 17,21-di-propionate the crystals whereof are liable to growth in an aerosol propellent into a from showing no such growth tendency

Info

Publication number
YU39602B
YU39602B YU1086/73A YU108673A YU39602B YU 39602 B YU39602 B YU 39602B YU 1086/73 A YU1086/73 A YU 1086/73A YU 108673 A YU108673 A YU 108673A YU 39602 B YU39602 B YU 39602B
Authority
YU
Yugoslavia
Prior art keywords
growth
beclomethasone
liable
whereof
propionate
Prior art date
Application number
YU1086/73A
Other languages
English (en)
Other versions
YU108673A (en
Inventor
P B Cook
J H Hunt
Original Assignee
Allen & Hanburys Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=10112152&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=YU39602(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Allen & Hanburys Ltd filed Critical Allen & Hanburys Ltd
Publication of YU108673A publication Critical patent/YU108673A/xx
Publication of YU39602B publication Critical patent/YU39602B/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/008—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy comprising drug dissolved or suspended in liquid propellant for inhalation via a pressurized metered dose inhaler [MDI]

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Otolaryngology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pulmonology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Steroid Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
YU1086/73A 1972-04-20 1973-04-20 Process for the conversion of beclomethasone 17,21-di-propionate the crystals whereof are liable to growth in an aerosol propellent into a from showing no such growth tendency YU39602B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GB1842172A GB1429184A (en) 1972-04-20 1972-04-20 Physically anti-inflammatory steroids for use in aerosols

Publications (2)

Publication Number Publication Date
YU108673A YU108673A (en) 1982-06-30
YU39602B true YU39602B (en) 1985-03-20

Family

ID=10112152

Family Applications (1)

Application Number Title Priority Date Filing Date
YU1086/73A YU39602B (en) 1972-04-20 1973-04-20 Process for the conversion of beclomethasone 17,21-di-propionate the crystals whereof are liable to growth in an aerosol propellent into a from showing no such growth tendency

Country Status (23)

Country Link
US (2) US4414209A (en:Method)
JP (1) JPS531814B2 (en:Method)
AR (1) AR196524A1 (en:Method)
AT (1) AT348115B (en:Method)
AU (1) AU471577B2 (en:Method)
BE (1) BE798458A (en:Method)
CA (1) CA994753A (en:Method)
DE (1) DE2320111C2 (en:Method)
DK (1) DK134923B (en:Method)
ES (1) ES413911A1 (en:Method)
FI (1) FI53067C (en:Method)
FR (1) FR2182981B1 (en:Method)
GB (1) GB1429184A (en:Method)
HU (1) HU171209B (en:Method)
IE (1) IE37541B1 (en:Method)
IL (1) IL42038A (en:Method)
LU (1) LU67462A1 (en:Method)
NL (1) NL157797B (en:Method)
NO (1) NO140303C (en:Method)
PH (1) PH13620A (en:Method)
SE (1) SE399642B (en:Method)
YU (1) YU39602B (en:Method)
ZA (1) ZA732713B (en:Method)

Families Citing this family (320)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX3864E (es) * 1975-05-27 1981-08-26 Syntex Corp Un proceso para prepara el compuesto cristalino 6-fluiro-11b 21-dihiroxi-16 17-isopropilidendioxipregna-1 4-dien-3 20-diona
US4933168A (en) * 1975-05-27 1990-06-12 Syntex Pharmaceuticals International Limited Stable, crystalline flunisolide
GB1571629A (en) * 1977-11-30 1980-07-16 Fisons Ltd Pharmaceutical compositions containing beclomethasone dipropionate
IT1121513B (it) * 1979-05-28 1986-04-02 Chiesi Farma Spa Processo per la conversione di umo steroide antiinfiammatorio in una forma suscettibile di essere somministarta come aerosol
ATE3774T1 (de) * 1980-05-02 1983-06-15 Schering Corporation Beclomethason-ester-solvate, verfahren zu ihrer herstellung und herstellung einer formulierung.
FI63672C (fi) * 1980-05-19 1983-08-10 Orion Yhtymae Oy Foerfarande foer framstaellning av en blandning av beklometasondipropionat och triklorfluormetan eller diklordifluormetan
KR890000664B1 (ko) * 1981-10-19 1989-03-22 바리 안소니 뉴우샘 미분된 베클로메타손 디프로피오네이트 일수화물의 제조방법
GB8432063D0 (en) * 1984-12-19 1985-01-30 Riker Laboratories Inc Physically modified steroids
US5962490A (en) * 1987-09-25 1999-10-05 Texas Biotechnology Corporation Thienyl-, furyl- and pyrrolyl-sulfonamides and derivatives thereof that modulate the activity of endothelin
US5562608A (en) * 1989-08-28 1996-10-08 Biopulmonics, Inc. Apparatus for pulmonary delivery of drugs with simultaneous liquid lavage and ventilation
US5736509A (en) * 1990-12-14 1998-04-07 Texas Biotechnology Corporation Cyclic peptide surface feature mimics of endothelin
US5674471A (en) * 1991-12-12 1997-10-07 Glaxo Group Limited Aerosol formulations containing P134a and salbutamol
US5744123A (en) * 1991-12-12 1998-04-28 Glaxo Group Limited Aerosol formulations containing P134a and particulate medicaments
US5736124A (en) * 1991-12-12 1998-04-07 Glaxo Group Limited Aerosol formulations containing P134a and particulate medicament
DK0616524T3 (da) 1991-12-12 1999-06-21 Glaxo Group Ltd Lægemidler
IL104068A (en) 1991-12-12 1998-10-30 Glaxo Group Ltd Surfactant-free pharmaceutical aerosol formulation comprising 1,1,1,2-tetrafluoroethane or 1,1,1,2,3,3,3-heptafluoro-n- propane as propellant
US5658549A (en) * 1991-12-12 1997-08-19 Glaxo Group Limited Aerosol formulations containing propellant 134a and fluticasone propionate
US5683676A (en) * 1991-12-12 1997-11-04 Glaxo Group Limited Canister containing aerosol formulations containing P134a and particulate medicaments
US5916540A (en) 1994-10-24 1999-06-29 Glaxo Group Limited Aerosol formulations containing P134A and/or P227 and particulate medicament
US7105152B1 (en) 1991-12-18 2006-09-12 3M Innovative Properties Company Suspension aerosol formulations
US7101534B1 (en) 1991-12-18 2006-09-05 3M Innovative Properties Company Suspension aerosol formulations
US5301664A (en) * 1992-03-06 1994-04-12 Sievers Robert E Methods and apparatus for drug delivery using supercritical solutions
CA2115065C (en) * 1992-06-12 2000-10-03 Kiyoyuki Sakon Ultrafine particle powder for inhalation and method for production thereof
MX9304585A (es) 1992-07-31 1994-03-31 Glaxo Group Ltd Formulacion farmaceutica en aerosol, lata adecuada para liberar la formulacion e inhalador de dosis dosificada que comprende la lata.
EP0619115A1 (en) * 1993-04-01 1994-10-12 Amgen Inc. Container comprising a metered dose valve and microparticles of a drug for topical treatment of skin disorders
US6030991A (en) * 1993-05-20 2000-02-29 Texas Biotechnology Corp. Benzenesulfonamides and the use thereof to modulate the activity of endothelin
US6376523B1 (en) 1994-05-20 2002-04-23 Texas Biotechnology Corporation Benzenesulfonamides and the use thereof to modulate the activity of endothelin
US6541498B2 (en) 1993-05-20 2003-04-01 Texas Biotechnology Benzenesulfonamides and the use thereof to modulate the activity of endothelin
US6342610B2 (en) 1993-05-20 2002-01-29 Texas Biotechnology Corp. N-aryl thienyl-, furyl-, and pyrrolyl-sulfonamides and derivatives thereof that modulate the activity of endothelin
US6613804B2 (en) 1993-05-20 2003-09-02 Encysive Pharmaceuticals, Inc. Biphenylsulfonamides and derivatives thereof that modulate the activity of endothelin
US6551618B2 (en) 1994-03-15 2003-04-22 University Of Birmingham Compositions and methods for delivery of agents for neuronal regeneration and survival
JP3119487B2 (ja) 1994-08-09 2000-12-18 シェーリング コーポレイション ベクロメタゾンジプロピオネートフレオン（登録商標）包接化合物の調製プロセス
US5980949A (en) * 1994-10-03 1999-11-09 Astra Aktiebolag Formulation for inhalation
US5983956A (en) * 1994-10-03 1999-11-16 Astra Aktiebolag Formulation for inhalation
US5863902A (en) * 1995-01-06 1999-01-26 Sibia Neurosciences, Inc. Methods of treating neurodegenerative disorders using protease inhibitors
US5804560A (en) * 1995-01-06 1998-09-08 Sibia Neurosciences, Inc. Peptide and peptide analog protease inhibitors
US5646130A (en) * 1995-06-30 1997-07-08 Ocean University Of Oingdao Low molecular weight sulfated polysaccharides and uses thereof
US5977117A (en) * 1996-01-05 1999-11-02 Texas Biotechnology Corporation Substituted phenyl compounds and derivatives thereof that modulate the activity of endothelin
US5700487A (en) * 1996-03-04 1997-12-23 The Ohio State University Treatment of pulmonary inflammation
US5958905A (en) * 1996-03-26 1999-09-28 Texas Biotechnology Corporation Phosphoramidates, phosphinic amides and related compounds and the use thereof to modulate the activity of endothelin
US5804585A (en) 1996-04-15 1998-09-08 Texas Biotechnology Corporation Thieno-pyridine sulfonamides derivatives thereof and related compounds that modulate the activity of endothelin
AU736301B2 (en) * 1996-05-01 2001-07-26 Imarx Therapeutics, Inc. Methods for delivering compounds into a cell
US6416960B1 (en) 1996-08-08 2002-07-09 Prolume, Ltd. Detection and visualization of neoplastic tissues and other tissues
SE9603725D0 (sv) * 1996-10-11 1996-10-11 Astra Ab New teatment
US6380222B2 (en) 1996-10-11 2002-04-30 Astrazeneca Ab Use of an H+, K+-atpase inhibitor in the treatment of nasal polyps
CA2271717A1 (en) 1996-12-12 1998-06-18 Prolume, Ltd. Apparatus and method for detecting and identifying infectious agents
SE9700135D0 (sv) * 1997-01-20 1997-01-20 Astra Ab New formulation
SE9700133D0 (sv) * 1997-01-20 1997-01-20 Astra Ab New formulation
CA2281090C (en) 1997-04-28 2005-06-07 Texas Biotechnology Corporation Sulfonamide compounds and salts for treatment of endothelin-mediated disorders
US5783705A (en) 1997-04-28 1998-07-21 Texas Biotechnology Corporation Process of preparing alkali metal salys of hydrophobic sulfonamides
US6342611B1 (en) * 1997-10-10 2002-01-29 Cytovia, Inc. Fluorogenic or fluorescent reporter molecules and their applications for whole-cell fluorescence screening assays for capsases and other enzymes and the use thereof
US6362009B1 (en) 1997-11-21 2002-03-26 Merck & Co., Inc. Solid phase synthesis of heterocycles
EP1054694A2 (en) 1998-02-13 2000-11-29 Selective Genetics, Inc. Concurrent flow mixing methods and apparatuses for the preparation of gene therapy vectors and compositions prepared thereby
EP1925320A3 (en) 1998-03-27 2008-09-03 Prolume, Ltd. Luciferases, fluorescent proteins, nucleic acids encoding the luciferases and fluorescent proteins and the use thereof in diagnostics
AU5116099A (en) * 1998-07-21 2000-02-14 Sui Xiong Cai Novel fluorescence dyes and their applications for whole cell fluorescence screening assays for caspases, peptidases, proteases and other enzymes and the use thereof
US6667299B1 (en) * 2000-03-16 2003-12-23 Hollis-Eden Pharmaceuticals, Inc. Pharmaceutical compositions and treatment methods
AU1624801A (en) 1999-11-19 2001-05-30 Corvas International, Inc. Plasminogen activator inhibitor antagonists related applications
US6638977B1 (en) 1999-11-19 2003-10-28 Corvas International, Inc. Plasminogen activator inhibitor antagonists
US7897140B2 (en) 1999-12-23 2011-03-01 Health Research, Inc. Multi DTPA conjugated tetrapyrollic compounds for phototherapeutic contrast agents
MXPA02006461A (es) 1999-12-31 2003-09-05 Texas Biotechnology Corp Sulfonamidas y derivados de las mismas que modulan la actividad de endotelina.
US7109315B2 (en) 2000-03-15 2006-09-19 Bruce J. Bryan Renilla reniformis fluorescent proteins, nucleic acids encoding the fluorescent proteins and the use thereof in diagnostics, high throughput screening and novelty items
US6544497B2 (en) 2001-02-15 2003-04-08 Aeropharm Technology Incorporated Modulated release particles for aerosol delivery
US6485707B2 (en) 2001-02-15 2002-11-26 Aeropharm Technology Incorporated Modulated release particles for aerosol delivery
US6596262B2 (en) 2001-02-15 2003-07-22 Aeropharm Technology Incorporated Modulated release particles for aerosol delivery
GB0208742D0 (en) 2002-04-17 2002-05-29 Bradford Particle Design Ltd Particulate materials
US20030129203A1 (en) * 2001-08-27 2003-07-10 Nautilus Biotech S.A. Mutant recombinant adeno-associated viruses
US20050065118A1 (en) * 2001-10-16 2005-03-24 Jing Wang Organosulfur inhibitors of tyrosine phosphatases
AUPR868201A0 (en) * 2001-11-05 2001-11-29 Thorlock International Limited Q-factor switching method and apparatus for detecting nuclear quadrupole and nuclear magnetic resonance signals
US7482366B2 (en) 2001-12-21 2009-01-27 X-Ceptor Therapeutics, Inc. Modulators of LXR
AU2002351412B2 (en) 2001-12-21 2010-05-20 Exelixis Patent Company Llc Modulators of LXR
ES2367539T3 (es) * 2001-12-21 2011-11-04 X-Ceptor Therapeutics, Inc. Moduladores heterocíclicos de receptores nucleares.
US7582284B2 (en) 2002-04-17 2009-09-01 Nektar Therapeutics Particulate materials
US20030199594A1 (en) * 2002-04-23 2003-10-23 Rasik Shah Helium propellant composition for use with aerosols
US20040001801A1 (en) * 2002-05-23 2004-01-01 Corvas International, Inc. Conjugates activated by cell surface proteases and therapeutic uses thereof
AU2003248747A1 (en) 2002-06-27 2004-01-19 Health Research, Inc. Fluorinated chlorin and bacteriochlorin photosensitizers for photodynamic therapy
WO2004005289A2 (en) 2002-07-02 2004-01-15 Health Research, Inc. Efficient synthesis of pyropheophorbide a and its derivatives
US20050202438A1 (en) * 2002-09-09 2005-09-15 Rene Gantier Rational directed protein evolution using two-dimensional rational mutagenesis scanning
AU2003263552A1 (en) * 2002-09-09 2004-03-29 Nautilus Biotech Rational evolution of cytokines for higher stability, the cytokines and encoding nucleic acid molecules
US20060020396A1 (en) * 2002-09-09 2006-01-26 Rene Gantier Rational directed protein evolution using two-dimensional rational mutagenesis scanning
BR0316397A (pt) 2002-11-19 2005-09-27 Achillion Pharmaceuticals Inc Tiouréias aril substituìdas e compostos relacionados como inibidores de replicação viral
WO2004060260A2 (en) * 2002-12-18 2004-07-22 Glaxo Group Limited Drug delivery system with vented mouthpiece
KR101363658B1 (ko) 2003-03-05 2014-02-14 할로자임, 아이엔씨 가용성 하이알우로니다제 당단백질 (ｓＨＡＳＥＧＰ), 이를 제조하는 방법, 용도 및 이를 포함하는 약학 조성물
US20060104968A1 (en) 2003-03-05 2006-05-18 Halozyme, Inc. Soluble glycosaminoglycanases and methods of preparing and using soluble glycosaminogly ycanases
US7871607B2 (en) * 2003-03-05 2011-01-18 Halozyme, Inc. Soluble glycosaminoglycanases and methods of preparing and using soluble glycosaminoglycanases
AU2004247013B2 (en) * 2003-05-14 2010-07-08 Neurogenetic Pharmaceuticals, Inc. Compounds and uses thereof in modulating amyloid beta
ATE439837T1 (de) * 2003-06-03 2009-09-15 Novartis Ag 5-gliedrige heterocyclische p-38 inhibitoren
EP1911754B1 (en) 2003-08-13 2013-10-09 Takeda Pharmaceutical Company Limited Dipeptidyl peptidase inhibitors
US7420000B2 (en) 2003-09-10 2008-09-02 University Of Southern California Amino phosphonate and amino bis-phosphonate derivatives
US20050148534A1 (en) * 2003-09-22 2005-07-07 Castellino Angelo J. Small molecule compositions and methods for increasing drug efficiency using compositions thereof
WO2005090370A1 (en) 2004-02-05 2005-09-29 The Regents Of The University Of California Pharmacologically active agents containing esterified phosphonates and methods for use thereof
WO2005090282A1 (en) 2004-03-12 2005-09-29 Ligand Pharmaceuticals Incorporated Androgen receptor modulator compounds and methods
MXPA06013381A (es) 2004-05-20 2007-03-01 Scripps Research Inst Estabilizacion de transtiretina.
JP2008503490A (ja) * 2004-06-17 2008-02-07 センジェント・セラピューティクス・インコーポレイテッド チロシンホスファターゼの三置換窒素調節物質
US20060135483A1 (en) * 2004-07-09 2006-06-22 Cheruvallath Zacharia S Oxygen/nitrogen heterocycle inhibitors of tyrosine phosphatases
EA200700225A1 (ru) 2004-07-12 2008-02-28 Айдан Фармасьютикалз, Инк. Аналоги тетрапептида
WO2006028970A1 (en) * 2004-09-02 2006-03-16 Cengent Therapeutics, Inc. Derivatives of thiazole and thiadiazole inhibitors of tyrosine phosphatases
CN102379872A (zh) 2004-09-17 2012-03-21 怀特黑德生物医学研究院 抑制α-突触核蛋白毒性的化合物、组合物和方法
US7998930B2 (en) * 2004-11-04 2011-08-16 Hanall Biopharma Co., Ltd. Modified growth hormones
US7872124B2 (en) 2004-12-21 2011-01-18 Takeda Pharmaceutical Company Limited Dipeptidyl peptidase inhibitors
ATE534652T1 (de) 2005-04-01 2011-12-15 Univ California Phosphono-pent-2-en-1-yl-nukleoside und analoga
EP1877434A2 (en) * 2005-05-04 2008-01-16 Nautilus Biotech Modified interferon-gamma polypeptides and methods for using modified interferon-gamma polypeptides
NZ560354A (en) 2005-06-17 2010-10-29 Ligand Pharm Inc Androgen receptor modulator compounds and methods
US20100098640A1 (en) * 2005-06-20 2010-04-22 Cohen Seth M Multidentate Pyrone-Derived Chelators for Medicinal Imaging and Chelation
US20080058282A1 (en) 2005-08-30 2008-03-06 Fallon Joan M Use of lactulose in the treatment of autism
US8492428B2 (en) * 2005-09-20 2013-07-23 Mayo Foundation For Medical Education And Research Small-molecule botulinum toxin inhibitors
US8119655B2 (en) 2005-10-07 2012-02-21 Takeda Pharmaceutical Company Limited Kinase inhibitors
WO2007047995A2 (en) 2005-10-21 2007-04-26 Catalyst Biosciences, Inc. Modified proteases that inhibit complement activation
US8138361B2 (en) * 2005-12-28 2012-03-20 The Trustees Of The University Of Pennsylvania C-10 carbamates of taxanes
EP2013182B1 (en) * 2006-03-13 2013-09-04 Kyorin Pharmaceutical Co., Ltd. Aminoquinolones as gsk-3 inhibitors
US20080003202A1 (en) * 2006-03-28 2008-01-03 Thierry Guyon Modified interferon-beta (IFN-beta) polypeptides
CN101460161A (zh) * 2006-03-29 2009-06-17 弗尔德里克斯制药股份有限公司 α-突触核蛋白毒性的抑制
US20070286814A1 (en) * 2006-06-12 2007-12-13 Medispray Laboratories Pvt. Ltd. Stable aerosol pharmaceutical formulations
EP2423306A1 (en) 2006-06-19 2012-02-29 Catalyst Biosciences, Inc. Modified coagulation factor IX polypeptides and use thereof for treatment
ES2439994T3 (es) 2006-08-28 2014-01-27 Kyowa Hakko Kirin Co., Ltd. Anticuerpos antagonistas monoclonales humanos específicos de LIGHT humano
ES2396256T3 (es) 2006-09-21 2013-02-20 Kyorin Pharmaceutical Co., Ltd. Inhibidores de serina hidrolasa
JP2010505961A (ja) 2006-10-09 2010-02-25 タケダ サン ディエゴ インコーポレイテッド キナーゼ阻害剤
KR20090068277A (ko) 2006-10-09 2009-06-25 다케다 야쿠힌 고교 가부시키가이샤 키나아제 억제제
CA2667961A1 (en) 2006-10-31 2008-05-08 Takeda Pharmaceutical Company Limited Mapk/erk kinase inhibitors
WO2008057604A2 (en) * 2006-11-08 2008-05-15 The Regents Of The University Of California Small molecule therapeutics, syntheses of analogues and derivatives and methods of use
WO2009070164A1 (en) 2007-11-28 2009-06-04 University Of Central Florida Vigor enhancement via administration of pyrimidine derivatives
EP2120998B1 (en) 2006-11-28 2013-08-07 HanAll Biopharma Co., Ltd. Modified erythropoietin polypeptides and uses thereof for treatment
TW200838536A (en) 2006-11-29 2008-10-01 Takeda Pharmaceutical Polymorphs of succinate salt of 2-[6-(3-amino-piperidin-1-yl)-3-methyl-2,4-dioxo-3,4-dihydro-2H-pyrimidin-1-ylmethy]-4-fluor-benzonitrile and methods of use therefor
EP2125739A1 (en) * 2006-12-22 2009-12-02 Encysive Pharmaceuticals, Inc. Modulators of c3a receptor and methods of use thereof
CN101677954A (zh) 2007-02-11 2010-03-24 Map药物公司 治疗性施用dhe用于快速减轻偏头痛而使副作用分布最小化的方法
PL2144604T3 (pl) 2007-02-28 2012-02-29 Conatus Pharmaceuticals Inc Sposoby leczenia przewlekłego zapalenia wątroby typu C z zastosowaniem RO 113-0830
BRPI0816798A2 (pt) * 2007-09-11 2016-10-11 Activx Biosciences Inc composto, composição farmacêutica, métodos para inibir a ação do glicogênio sintase cinase-3, e para tratar, prevenir ou melhorar uma doença, uso de um composto, e, artigo de fabricação
CN101855229A (zh) 2007-09-12 2010-10-06 埃迪威克斯生物科学公司 作为gsk-3抑制剂的螺环状氨基喹诺酮
WO2009042711A1 (en) 2007-09-25 2009-04-02 Takeda Pharmaceutical Company Limited Polo-like kinase inhibitors
US20090264421A1 (en) * 2007-10-05 2009-10-22 Bible Keith C Methods and Compositions for Treating Cancer
SG186008A1 (en) 2007-11-21 2012-12-28 Pharmaxis Ltd Haloallylamine inhibitors of ssao/vap-1 and uses therefor
EP2489656A1 (en) 2007-12-21 2012-08-22 Ligand Pharmaceuticals Inc. Selective androgen receptor modulators (sarms) and uses thereof
TWI395593B (zh) 2008-03-06 2013-05-11 Halozyme Inc 可活化的基質降解酵素之活體內暫時性控制
US8658163B2 (en) 2008-03-13 2014-02-25 Curemark Llc Compositions and use thereof for treating symptoms of preeclampsia
NZ601248A (en) 2008-04-14 2014-06-27 Halozyme Inc Modified hyaluronidases and uses in treating hyaluronan-associated diseases and conditions
US8084025B2 (en) 2008-04-18 2011-12-27 Curemark Llc Method for the treatment of the symptoms of drug and alcohol addiction
JP2011525535A (ja) 2008-06-24 2011-09-22 武田薬品工業株式会社 ＰＩ３Ｋ／ｍＴＯＲ阻害剤
PL2318035T3 (pl) 2008-07-01 2019-10-31 Curemark Llc Sposoby i kompozycje do leczenia objawów zaburzeń neurologicznych i zaburzeń zdrowia psychicznego
MX2011006110A (es) 2008-12-09 2011-06-24 Halozyme Inc Polipeptidos ph20 solubles extendidos y usos de los mismos.
CA2747703C (en) 2009-01-06 2021-06-15 Curemark Llc Compositions and methods for the treatment or the prevention of infections by e. coli
AU2010203709B2 (en) 2009-01-06 2014-05-22 Galenagen, Llc Compositions and methods for the treatment or prevention of Staphylococcus Aureus infections and for the Eradication or reduction of Staphylococcus Aureus on surfaces
EP2403523A1 (en) 2009-03-06 2012-01-11 Halozyme, Inc. Temperature sensitive mutants of matrix metalloprotease 1 und uses thereof
MX2011009414A (es) * 2009-03-11 2011-10-19 Kyorin Seiyaku Kk 7-cicloalquiloaminoquinolonas como inhibidores de gsk-3.
JP5730281B2 (ja) 2009-03-27 2015-06-10 武田薬品工業株式会社 ポリ（ａｄｐ−リボース）ポリメラーゼ（ｐａｒｐ）阻害剤
US9056050B2 (en) 2009-04-13 2015-06-16 Curemark Llc Enzyme delivery systems and methods of preparation and use
US8404728B2 (en) 2009-07-30 2013-03-26 Mayo Foundation For Medical Education And Research Small-molecule botulinum toxin inhibitors
WO2011014681A1 (en) 2009-07-30 2011-02-03 Takeda Pharmaceutical Company Limited Poly (ADP-Ribose) Polymerase (PARP) INHIBITORS
WO2011041293A1 (en) 2009-09-30 2011-04-07 Takeda Pharmaceutical Company Limited Pyrazolo [1, 5-a] pyrimidine derivatives as apoptosis signal-regulating kinase 1 inhibitors
US8871460B2 (en) 2009-11-09 2014-10-28 Neurogenetic Pharmaceuticals, Inc. Gamma-secretase modulatory compounds, methods for identifying same, and uses therefor
WO2011069002A1 (en) 2009-12-02 2011-06-09 Alquest Therapeutics, Inc. Organoselenium compounds and uses thereof
IN2012DN04858A (en:Method) * 2009-12-23 2015-09-25 Map Pharmaceuticals Inc
CN102791701B (zh) 2009-12-30 2014-02-12 深圳信立泰药业股份有限公司 作为二肽基肽酶iv(dpp-iv)抑制剂的3-(3-氨基哌啶-1-基)-5-氧代-1,2,4-三嗪衍生物
JP5711270B2 (ja) 2010-02-03 2015-04-30 武田薬品工業株式会社 アポトーシスシグナル調節キナーゼ１阻害剤
WO2011163636A2 (en) 2010-06-24 2011-12-29 The Regents Of The University Of California Compounds and uses thereof in modulating levels of various amyloid beta peptide alloforms
MX362974B (es) 2011-04-21 2019-02-28 Curemark Llc Compuestos para el tratamiento de alteraciones neuropsiquiatricas.
WO2012177962A1 (en) 2011-06-23 2012-12-27 Map Pharmaceuticals, Inc. Novel fluoroergoline analogs
WO2013037482A1 (en) 2011-09-15 2013-03-21 Phenex Pharmaceuticals Ag Farnesoid x receptor agonists for cancer treatment and prevention
CA2859173A1 (en) 2011-12-19 2013-06-27 Map Pharmaceuticals, Inc. Novel iso-ergoline derivatives
SG11201403433PA (en) 2011-12-21 2014-07-30 Map Pharmaceuticals Inc Novel neuromodulatory compounds
IL298330B1 (en) 2011-12-30 2025-03-01 Halozyme Inc PH20 Polypeptide Variants, Formulations and Uses Thereof
IN2012DE00661A (en:Method) 2012-03-07 2015-08-21 Univ Delhi
US9913822B2 (en) 2012-04-04 2018-03-13 Halozyme, Inc. Combination therapy with an anti-hyaluronan agent and therapeutic agent
EP3438087A1 (en) 2012-05-02 2019-02-06 Boehringer Ingelheim International GmbH Substituted 3-haloallylamine inhibitors of ssao and uses thereof
US10350278B2 (en) 2012-05-30 2019-07-16 Curemark, Llc Methods of treating Celiac disease
WO2013187965A1 (en) 2012-06-14 2013-12-19 Mayo Foundation For Medical Education And Research Pyrazole derivatives as inhibitors of stat3
US9012640B2 (en) 2012-06-22 2015-04-21 Map Pharmaceuticals, Inc. Cabergoline derivatives
US9074186B2 (en) 2012-08-15 2015-07-07 Boston Medical Center Corporation Production of red blood cells and platelets from stem cells
EP2934143A4 (en) 2012-12-21 2016-06-15 Map Pharmaceuticals Inc NOVEL DERIVATIVES OF METHYSERGIDE
US20150196625A9 (en) 2013-01-07 2015-07-16 Rudolph D. Paladini Metal Sensitive Mutants of Matrix Metalloproteases and uses thereof
US11058659B2 (en) 2013-02-22 2021-07-13 University Of Southern California Methods and compositions for the treatment of ophalmic diseases and disorders
EP2968296B1 (en) 2013-03-12 2020-09-02 The Regents of the University of California Gamma-secretase modulators
EP2967049B1 (en) 2013-03-15 2020-09-02 University Of Southern California Methods, compounds, and compositions for the treatment of angiotensin-related diseases
ES2891755T3 (es) 2013-06-06 2022-01-31 Pf Medicament Anticuerpos anti-C10orf54 y utilizaciones de los mismos
TW201534726A (zh) 2013-07-03 2015-09-16 Halozyme Inc 熱穩定ｐｈ２０玻尿酸酶變異體及其用途
EP3613418A1 (en) 2014-01-17 2020-02-26 Ligand Pharmaceuticals, Inc. Methods and compositions for modulating hormone levels
GB201403775D0 (en) 2014-03-04 2014-04-16 Kymab Ltd Antibodies, uses & methods
RU2016148364A (ru) 2014-05-12 2018-06-13 Конатус Фармасьютикалз, Инк. Лечение осложнений хронического заболевания печени
AU2015266958A1 (en) 2014-05-28 2016-12-08 Agenus Inc. Anti-GITR antibodies and methods of use thereof
US9499514B2 (en) 2014-07-11 2016-11-22 Celgene Corporation Antiproliferative compounds and methods of use thereof
NZ746680A (en) 2014-10-14 2020-07-31 Halozyme Inc Compositions of adenosine deaminase-2 (ada2), variants thereof and methods of using same
WO2016065264A1 (en) 2014-10-24 2016-04-28 Biogen Ma Inc. Diterpenoid derivatives and methods of use thereof
JP6672296B2 (ja) 2014-10-31 2020-03-25 ザ ジェネラル ホスピタル コーポレイション 強力なγ−セクレターゼモジュレータ
CN114230664B (zh) 2014-12-11 2025-01-03 皮埃尔法布雷医药公司 抗c10orf54抗体及其用途
WO2016106221A1 (en) 2014-12-22 2016-06-30 The Rockefeller University Anti-mertk agonistic antibodies and uses thereof
JP2018502889A (ja) 2015-01-20 2018-02-01 エックスオーシー ファーマシューティカルズ インコーポレイテッドＸｏｃ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ， Ｉｎｃ イソエルゴリン化合物およびその使用
MX2017009405A (es) 2015-01-20 2018-01-18 Xoc Pharmaceuticals Inc Compuestos de tipo ergolina y usos de estos.
CN108064169B (zh) 2015-03-03 2022-02-11 科马布有限公司 抗体、用途和方法
US20180156807A1 (en) 2015-04-29 2018-06-07 New York University Method for treating high-grade gliomas
LT3303394T (lt) 2015-05-29 2020-10-12 Agenus Inc. Anti-ctla-4 antikūnai ir jų naudojimo būdai
PT3640345T (pt) 2015-08-17 2021-12-29 Kura Oncology Inc Métodos de tratamento de doentes com cancro usando inibidores da farnesiltransferase
KR102434314B1 (ko) 2015-09-01 2022-08-19 아게누스 인코포레이티드 항-pd-1 항체 및 이를 이용하는 방법
WO2017079566A1 (en) 2015-11-05 2017-05-11 Conatus Pharmaceuticals, Inc. Caspase inhibitors for use in the treatment of liver cancer
US10112924B2 (en) 2015-12-02 2018-10-30 Astraea Therapeutics, Inc. Piperdinyl nociceptin receptor compounds
JP7011596B2 (ja) 2015-12-02 2022-02-10 アストライア セラピューティクス， エルエルシー ピペリジニルノシセプチン受容体化合物
CA3010286A1 (en) 2015-12-31 2017-07-06 Conatus Pharmaceuticals Inc. Methods of using caspase inhibitors in treatment of liver disease
JP6880037B2 (ja) 2016-01-08 2021-06-02 セルジーン コーポレイション がんの治療方法と、治療法に対する臨床的感度の予測因子としてのバイオマーカーの使用
TWI733734B (zh) 2016-01-08 2021-07-21 美商西建公司 2-(4-氯苯基)-n-((2-(2,6-二氧六氫吡啶-3-基)-1-氧基異吲哚啉-5-基)甲基)-2,2-二氟乙醯胺之固體型式，及其醫藥組合物及用途
AR107321A1 (es) 2016-01-08 2018-04-18 Celgene Corp Compuestos antiproliferativos, y sus composiciones farmacéuticas y usos
WO2017151836A1 (en) 2016-03-04 2017-09-08 East Carolina University J-series prostaglandin-ethanolamides as novel therapeutics for skin and/or oral disorders
EP3426301A4 (en) 2016-03-08 2019-11-06 Los Gatos Pharmaceuticals, Inc. VERBUNDNANOPARTICLES AND USES THEREOF
EP3426352A4 (en) 2016-03-08 2019-11-13 Los Gatos Pharmaceuticals, Inc. CAMPTOTHECIN DERIVATIVES AND USES THEREOF
US10047077B2 (en) 2016-04-13 2018-08-14 Skyline Antiinfectives, Inc. Deuterated O-sulfated beta-lactam hydroxamic acids and deuterated N-sulfated beta-lactams
WO2017184968A1 (en) 2016-04-22 2017-10-26 Kura Oncology, Inc. Methods of selecting cancer patients for treatment with farnesyltransferase inhibitors
WO2017194789A1 (en) 2016-05-13 2017-11-16 Institut Pasteur Inhibition of beta-2 nicotinic acetylcholine receptors to treat alzheimer's disease pathology
CA3024508A1 (en) 2016-05-27 2017-11-30 Agenus Inc. Anti-tim-3 antibodies and methods of use thereof
CA3030099A1 (en) 2016-07-08 2018-01-11 Staten Biotechnology B.V. Anti-apoc3 antibodies and methods of use thereof
WO2018035281A1 (en) 2016-08-17 2018-02-22 North Carolina State University Northern-southern route to synthesis of bacteriochlorins
EP3526256B1 (en) 2016-10-11 2025-09-10 Agenus Inc. Anti-lag-3 antibodies and methods of use thereof
KR20190082247A (ko) 2016-11-03 2019-07-09 쿠라 온콜로지, 인크. 파르네실전달효소 억제제를 이용하여 암 환자를 치료하는 방법
US11779604B2 (en) 2016-11-03 2023-10-10 Kymab Limited Antibodies, combinations comprising antibodies, biomarkers, uses and methods
US11332521B2 (en) 2016-11-07 2022-05-17 Neuracle Science Co., Ltd. Anti-family with sequence similarity 19, member A5 antibodies and method of use thereof
WO2018089692A1 (en) 2016-11-09 2018-05-17 Phloronol, Inc. Eckol derivatives, methods of synthesis and uses thereof
WO2018102252A1 (en) 2016-11-30 2018-06-07 North Carolina State University Methods for making bacteriochlorin macrocycles comprising an annulated isocyclic ring and related compounds
MD3551660T2 (ro) 2016-12-07 2024-03-31 Agenus Inc Anticorpi anti-CTLA-4 și procedee de utilizare a acestora
KR102603681B1 (ko) 2016-12-07 2023-11-17 아게누스 인코포레이티드 항체 및 이의 사용방법
US10137121B2 (en) 2017-02-21 2018-11-27 Kura Oncology, Inc. Methods of treating cancer with farnesyltransferase inhibitors
KR20200090982A (ko) 2017-02-21 2020-07-29 쿠라 온콜로지, 인크. 파르네실트랜스퍼라제 억제제를 사용하는 암 환자의 치료 방법
US12226464B2 (en) 2017-04-10 2025-02-18 Curemark, Llc Compositions for treating addiction
AU2018253176B2 (en) 2017-04-13 2023-02-02 Agenus Inc. Anti-CD137 antibodies and methods of use thereof
CN110506056A (zh) 2017-04-21 2019-11-26 斯塔滕生物技术有限公司 抗apoc3抗体和其使用方法
TWI805582B (zh) 2017-05-01 2023-06-21 美商艾吉納斯公司 抗ｔｉｇｉｔ抗體類和使用彼等之方法
US10085999B1 (en) 2017-05-10 2018-10-02 Arixa Pharmaceuticals, Inc. Beta-lactamase inhibitors and uses thereof
BR112019025420A2 (pt) 2017-06-01 2020-06-16 Xoc Pharmaceuticals, Inc. Compostos policíclicos e usos destes
IL271587B2 (en) 2017-06-22 2024-05-01 Catalyst Biosciences Inc Modified membrane type serine protease 1 (mtsp-1) polypeptides and methods of use
JP2020525459A (ja) 2017-06-26 2020-08-27 アンスティテュ・パストゥール Ｈｉｖリザーバーを排除し、ウイルス負荷を低減する処置
WO2019003162A1 (en) 2017-06-27 2019-01-03 Neuracle Science Co., Ltd. USE OF ANTIBODIES DIRECTED AGAINST A SIMILARITY FAMILY OF SEQUENCE 19, MEMBER A5, FOR THE TREATMENT OF GLAUCOMA
US11560425B2 (en) 2017-06-27 2023-01-24 Neuracle Science Co., Ltd. Use of anti-FAM19A5 antibodies for treating cancers
US11155613B2 (en) 2017-06-27 2021-10-26 Neuracle Science Co., Ltd. Use of anti-FAM19A5 antibodies for treating fibrosis
JP7076059B2 (ja) 2017-06-27 2022-05-27 ニューラクル サイエンス カンパニー リミテッド 抗ｆａｍ１９ａ５抗体及びその用途
US11168326B2 (en) 2017-07-11 2021-11-09 Actym Therapeutics, Inc. Engineered immunostimulatory bacterial strains and uses thereof
JP7325400B2 (ja) 2017-08-07 2023-08-14 クラ オンコロジー， インコーポレイテッド ファルネシルトランスフェラーゼ阻害剤を用いてがんを治療する方法
US10806730B2 (en) 2017-08-07 2020-10-20 Kura Oncology, Inc. Methods of treating cancer with farnesyltransferase inhibitors
EP4265257A1 (en) 2017-09-01 2023-10-25 East Carolina University Combination of a j-series prostaglandin-ethanolamide and a checkpoint inhibitor for use in treating cancer
EP3692171A4 (en) 2017-10-02 2021-06-23 Neuracle Science Co., Ltd USING ANTI-FAMILY WITH SEQUENCE LIKE 19, ELEMENT A5 ANTIBODIES FOR TREATMENT AND DIAGNOSIS OF MENTAL DISORDERS
KR20200074975A (ko) 2017-10-31 2020-06-25 스태튼 바이오테크놀로지 비.브이. 항-ApoC3 항체 및 이의 사용 방법
WO2019099353A1 (en) 2017-11-15 2019-05-23 California State University Northridge Compositions and methods for the treatment and prevention of cancer
WO2019113269A1 (en) 2017-12-08 2019-06-13 Kura Oncology, Inc. Methods of treating cancer patients with farnesyltransferase inhibitors
KR102866162B1 (ko) 2018-04-24 2025-10-01 주식회사 뉴라클사이언스 신경병성 통증의 치료를 위한 서열 유사성 19, 멤버 a5 항체를 갖는 항-패밀리의 용도
BR112020022669A2 (pt) 2018-05-08 2021-02-17 Neuracle Science Co., Ltd distribuição de vírus adenoassociado (aav) de anticorpos anti-fam19a5
KR102661891B1 (ko) 2018-05-10 2024-05-23 주식회사 뉴라클사이언스 서열 유사성 19, 멤버 a5 항체를 갖는 항-패밀리 및 그의 사용 방법
WO2019222435A1 (en) 2018-05-16 2019-11-21 Halozyme, Inc. Methods of selecting subjects for combination cancer therapy with a polymer-conjugated soluble ph20
WO2020006341A1 (en) 2018-06-29 2020-01-02 Conatus Pharmaceuticals, Inc. (s)-3-(2-(4-(benzyl)-3-oxopiperazin-1-yl)acetamido)-4-oxo-5-(2,3,5,6-tetrafluorophenoxy)pentanoic acid derivatives and related compounds as caspase inhibitors for treating cardiovascular diseases
WO2020014543A2 (en) 2018-07-11 2020-01-16 Actym Therapeutics, Inc. Engineered immunostimulatory bacterial strains and uses thereof
IL280199B2 (en) 2018-07-20 2025-08-01 Pf Medicament Receptor for vista
WO2020047161A2 (en) 2018-08-28 2020-03-05 Actym Therapeutics, Inc. Engineered immunostimulatory bacterial strains and uses thereof
EP3860713A2 (en) 2018-10-03 2021-08-11 Staten Biotechnology B.V. Antibodies specific for human and cynomolgus apoc3 and methods of use thereof
CA3115797A1 (en) 2018-10-16 2020-04-23 Neuracle Science Co., Ltd. Use of anti-fam19a5 antibodies
TW202031259A (zh) 2018-11-01 2020-09-01 美商庫拉腫瘤技術股份有限公司 以法尼基轉移酶(farnesyltransferase)抑制劑治療癌症之方法
JP2022507606A (ja) 2018-11-16 2022-01-18 ネオイミューンテック， インコーポレイテッド Ｉｌ－７タンパク質と免疫チェックポイント阻害剤の組み合わせで腫瘍を治療する方法
JP7407461B2 (ja) 2018-12-19 2024-01-04 シャイ・セラピューティクス・エルエルシー がん、炎症性疾患、ｒａｓ病、及び線維性疾患の処置のためのｒａｓスーパーファミリーと相互作用する化合物
WO2020128033A1 (en) 2018-12-20 2020-06-25 Institut Pasteur Cellular metabolism of hiv-1 reservoir seeding in cd4+ t cells
SG11202106599WA (en) 2018-12-21 2021-07-29 Kura Oncology Inc Therapies for squamous cell carcinomas
CN113227139B (zh) 2018-12-27 2024-10-29 纽洛可科学有限公司 抗fam19a5抗体治疗动脉粥样硬化的用途
JP7604376B2 (ja) 2018-12-28 2024-12-23 バーテックス ファーマシューティカルズ インコーポレイテッド 改変ウロキナーゼ型プラスミノゲンアクティベータポリペプチドおよび使用方法
US11613744B2 (en) 2018-12-28 2023-03-28 Vertex Pharmaceuticals Incorporated Modified urokinase-type plasminogen activator polypeptides and methods of use
US11447468B2 (en) 2019-02-06 2022-09-20 Dice Alpha, Inc. IL-17 ligands and uses thereof
ES2978570T3 (es) 2019-02-26 2024-09-16 Inspirna Inc Anticuerpos anti-MERTK de alta afinidad y sus usos
BR112021016728A2 (pt) 2019-02-27 2022-01-11 Actym Therapeutics Inc Bactérias imunostimulatórias projetadas para colonizar tumores, residentes em tumores células imunológicas e o microambiente tumoral
US12024709B2 (en) 2019-02-27 2024-07-02 Actym Therapeutics, Inc. Immunostimulatory bacteria engineered to colonize tumors, tumor-resident immune cells, and the tumor microenvironment
WO2020180663A1 (en) 2019-03-01 2020-09-10 Kura Oncology, Inc. Methods of treating cancer with farnesyltransferase inhibitors
SG11202109700PA (en) 2019-03-07 2021-10-28 Conatus Pharmaceuticals Inc Caspase inhibitors and methods of use thereof
US20220143006A1 (en) 2019-03-15 2022-05-12 Kura Oncology, Inc. Methods of treating cancer with farnesyltransferase inhibitors
KR20210144778A (ko) 2019-03-29 2021-11-30 쿠라 온콜로지, 인크. 파르네실트랜스퍼라제 억제제를 사용한 편평 세포 암종의 치료 방법
WO2020205387A1 (en) 2019-04-01 2020-10-08 Kura Oncology, Inc. Methods of treating cancer with farnesyltransferase inhibitors
BR112021020864A2 (pt) 2019-04-19 2021-12-14 Ligand Pharm Inc Formas cristalinas e métodos de produção de formas cristalinas de um composto
WO2020223583A1 (en) 2019-05-02 2020-11-05 Kura Oncology, Inc. Methods of treating acute myeloid leukemia with farnesyltransferase inhibitors
WO2020236828A1 (en) 2019-05-20 2020-11-26 Nirvana Sciences Inc. Narrow emission dyes, compositions comprising same, and methods for making and using same
EP3959293B1 (en) 2019-05-20 2024-11-13 NIRvana Sciences Inc. Narrow emission dyes, compositions comprising same, and methods for making and using same
WO2021042019A1 (en) 2019-08-30 2021-03-04 Agenus Inc. Anti-cd96 antibodies and methods of use thereof
EP4031534A1 (en) 2019-09-16 2022-07-27 Dice Alpha, Inc. Il-17a modulators and uses thereof
CA3177479A1 (en) 2019-11-12 2021-05-20 Actym Therapeutics, Inc. Immunostimulatory bacteria delivery platforms and their use for delivery of therapeutic products
WO2021146191A1 (en) 2020-01-13 2021-07-22 Neoimmunetech, Inc. Method of treating a tumor with a combination of il-7 protein and a bispecific antibody
AU2021217373A1 (en) 2020-02-05 2022-08-04 Neoimmunetech, Inc. Method of treating a solid tumor with a combination of an IL-7 protein and CAR-bearing immune cells
WO2021257828A1 (en) 2020-06-18 2021-12-23 Shy Therapeutics, Llc Substituted thienopyrimidines that interact with the ras superfamily for the treatment of cancers, inflammatory diseases, rasopathies, and fibrotic disease
JP2023532312A (ja) 2020-06-30 2023-07-27 プロセッタ バイオサイエンシズ， インク． イソキノリン誘導体、合成の方法及びそれらの使用
AU2021324883A1 (en) 2020-08-12 2023-03-23 Actym Therapeutics, Inc. Immunostimulatory bacteria-based vaccines, therapeutics, and rna delivery platforms
US11541009B2 (en) 2020-09-10 2023-01-03 Curemark, Llc Methods of prophylaxis of coronavirus infection and treatment of coronaviruses
KR20230098201A (ko) 2020-10-26 2023-07-03 네오이뮨텍, 인코퍼레이티드 줄기 세포 동원의 유도 방법
US20240101629A1 (en) 2020-11-02 2024-03-28 Neoimmunetech, Inc. Use of interleukin-7 for the treatment of coronavirus
US20240115675A1 (en) 2020-11-05 2024-04-11 Neoimmunetech, Inc. Method of treating a tumor with a combination of an il-7 protein and a nucleotide vaccine
US20240309015A1 (en) 2021-01-27 2024-09-19 Shy Therapeutics, Llc Methods for the Treatment of Fibrotic Disease
US20240124483A1 (en) 2021-01-27 2024-04-18 Shy Therapeutics, Llc Methods for the Treatment of Fibrotic Disease
BR112023018290A2 (pt) 2021-03-10 2023-12-12 Dice Molecules Sv Inc Inibidores da integrina alfa v beta 6 e alfa v beta 1 e usos dos mesmos
EP4326721A1 (en) 2021-04-22 2024-02-28 Protego Biopharma, Inc. Spirocyclic imidazolidinones and imidazolidinediones for treatment of light chain amyloidosis
EP4347568A1 (en) 2021-05-27 2024-04-10 Protego Biopharma, Inc. Heteroaryl diamide ire1/xbp1s activators
CA3218481A1 (en) 2021-06-14 2022-12-22 argenx BV Anti-il-9 antibodies and methods of use thereof
EP4402124A4 (en) 2021-10-22 2025-07-16 Prosetta Biosciences Inc NOVEL HOST-TARGETED SMALL MOLECULE PAN-RESPIRATORY ANTIVIRAL THERAPEUTIC AGENTS
WO2023081923A1 (en) 2021-11-08 2023-05-11 Frequency Therapeutics, Inc. Platelet-derived growth factor receptor (pdgfr) alpha inhibitors and uses thereof
CN119836296A (zh) 2021-12-30 2025-04-15 新免疫技术有限公司 用il-7蛋白和vegf拮抗剂的组合治疗肿瘤的方法
EP4433040A4 (en) 2022-01-03 2025-11-12 Lilac Therapeutics Inc ACYCLIC THIOL PRODRUGS
WO2023129577A1 (en) 2022-01-03 2023-07-06 Lilac Therapeutics, Inc. Cyclic thiol prodrugs
EP4463158A2 (en) 2022-03-02 2024-11-20 Mitopower, Inc. Novel prodrugs derived from nicotinic acid and ribose
GB2619907A (en) 2022-04-01 2023-12-27 Kanna Health Ltd Novel crystalline salt forms of mesembrine
WO2023201282A1 (en) 2022-04-14 2023-10-19 Bristol-Myers Squibb Company Novel gspt1 compounds and methods of use of the novel compounds
EP4507720A1 (en) 2022-04-14 2025-02-19 Fraunhofer-Gesellschaft zur Förderung der angewandten Forschung e.V. Alpha-1-antitrypsin for treating paramyxoviridae or orthomyxoviridae infections
EP4604988A1 (en) 2022-10-21 2025-08-27 Diagonal Therapeutics Inc. Heteromeric agonistic antibodies to il-18 receptor
US20240174673A1 (en) 2022-10-26 2024-05-30 Protego Biopharma, Inc. Spirocycle Containing Pyridine Compounds
WO2024092040A1 (en) 2022-10-26 2024-05-02 Protego Biopharma, Inc. Spirocycle containing bicyclic heteroaryl compounds
EP4608838A1 (en) 2022-10-26 2025-09-03 Protego Biopharma, Inc. Spirocycle containing pyridone compounds
EP4615485A1 (en) 2022-11-07 2025-09-17 NeoImmuneTech, Inc. Methods of treating a tumor with an unmethylated mgmt promoter
EP4626864A1 (en) 2022-11-30 2025-10-08 Protego Biopharma, Inc. Linear heteroaryl diamide ire1/xbp1s activators
EP4626865A1 (en) 2022-11-30 2025-10-08 Protego Biopharma, Inc. Cyclic pyrazole diamide ire1/xbp1s activators
WO2024194685A2 (en) 2023-03-17 2024-09-26 Oxitope Pharma B.V. Anti-phosphocholine antibodies and methods of use thereof
AU2024240129A1 (en) 2023-03-17 2025-10-09 Oxitope Pharma B.V. Anti-phosphocholine antibodies and methods of use thereof
AU2024254039A1 (en) 2023-04-07 2025-10-02 Diagonal Therapeutics Inc. Hinge-modified bispecific antibodies
WO2024211796A1 (en) 2023-04-07 2024-10-10 Diagonal Therapeutics Inc. Bispecific agonistic antibodies to activin a receptor like type 1 (alk1)
WO2024226471A2 (en) 2023-04-24 2024-10-31 Biomarin Pharmaceutical Inc. Compositions and methods for treating stxbp1 disorders
WO2024233642A1 (en) 2023-05-09 2024-11-14 Progentos Therapeutics, Inc. Heterocyclic compounds and uses thereof
US20250019450A1 (en) 2023-05-19 2025-01-16 Diagonal Therapeutics Inc. Bispecific agonistic antibodies to il12 receptor
WO2025010272A1 (en) 2023-07-03 2025-01-09 Neoimmunetech, Inc. Heterodimeric fc molecules and uses thereof
WO2025049818A1 (en) 2023-08-29 2025-03-06 Enosi Therapeutics Corporation Tnfr1 antagonists lacking agonist activity and uses thereof
WO2025046298A2 (en) 2023-09-01 2025-03-06 iTeos Belgium SA Anti-trem2 antibodies and methods of use
WO2025063888A1 (en) 2023-09-19 2025-03-27 Kancure Pte. Ltd. Survivin-targeted compounds
WO2025072423A1 (en) 2023-09-27 2025-04-03 Isosterix, Inc. Myst inhibitors
WO2025085416A1 (en) 2023-10-16 2025-04-24 Bristol-Myers Squibb Company Gspt1 compounds and methods of use of the compounds
WO2025090519A1 (en) 2023-10-23 2025-05-01 Diagonal Therapeutics Inc. Heteromeric agonistic antibodies to il-18 receptor
GB2636969A (en) 2023-11-24 2025-07-09 Ontrack Therapeutics Ltd Novel crystalline salt forms
WO2025133707A1 (en) 2023-12-19 2025-06-26 Vectory Therapeutics B.V. Anti-tdp-43 antibodies and uses thereof
WO2025147691A1 (en) 2024-01-04 2025-07-10 Innovo Therapeutics, Inc. Compositions and methods for degrading aryl hydrocarbon receptor nuclear translocator protein
WO2025179161A1 (en) 2024-02-21 2025-08-28 Innovo Therapeutics, Inc. Protein degrading compounds
WO2025201633A1 (en) 2024-03-26 2025-10-02 Chen Gefei An agent for reducing amyloid formation

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2849460A (en) * 1953-11-17 1958-08-26 Olin Mathieson Purification of steroids
BE556587A (en:Method) * 1957-01-31 1957-04-11
GB1047518A (en) * 1963-06-11 1966-11-02 Glaxo Lab Ltd 17ª‡-monoesters of 11,17,21-trihydroxy steroid compounds
US3320125A (en) * 1964-04-28 1967-05-16 Merck & Co Inc Inhalation aerosol composition
US3282791A (en) * 1965-08-17 1966-11-01 Merck & Co Inc Inhalation aerosol suspension of anhydrous disodium dexamethasone phosphate, propellents, and sorbitan trioleate
NL6810103A (en:Method) * 1967-07-31 1969-02-04
GB1253831A (en) * 1968-01-19 1971-11-17 Glaxo Lab Ltd 9alpha,21-DIHALOPREGNANE COMPOUNDS
US4119548A (en) * 1977-10-28 1978-10-10 Mobil Oil Corporation Reaction product of nickel thiobis(alkylphenolate) and thiobis(alkylphenol) and organic compositions containing the same

Also Published As

Publication number Publication date
JPS4919014A (en:Method) 1974-02-20
DK134923B (da) 1977-02-14
ATA352973A (de) 1978-06-15
NO140303C (no) 1979-08-08
LU67462A1 (en:Method) 1973-07-05
AU471577B2 (en) 1976-04-29
US4364923A (en) 1982-12-21
FI53067C (en:Method) 1978-02-10
HU171209B (hu) 1977-12-28
IL42038A0 (en) 1973-06-29
JPS531814B2 (en:Method) 1978-01-23
IE37541L (en) 1973-10-20
AU5466073A (en) 1974-10-24
IE37541B1 (en) 1977-08-17
NL7305438A (en:Method) 1973-10-23
DK134923C (en:Method) 1977-07-04
GB1429184A (en) 1976-03-24
FR2182981B1 (en:Method) 1976-12-31
IL42038A (en) 1976-11-30
BE798458A (fr) 1973-10-19
ES413911A1 (es) 1976-06-16
PH13620A (en) 1980-08-07
CA994753A (en) 1976-08-10
AR196524A1 (es) 1974-02-06
FI53067B (en:Method) 1977-10-31
DE2320111A1 (de) 1973-10-31
DE2320111C2 (de) 1986-12-04
US4414209A (en) 1983-11-08
NO140303B (no) 1979-04-30
AT348115B (de) 1979-01-25
YU108673A (en) 1982-06-30
ZA732713B (en) 1974-11-27
SE399642B (sv) 1978-02-27
FR2182981A1 (en:Method) 1973-12-14
NL157797B (nl) 1978-09-15

Similar Documents

Publication Publication Date Title
YU39602B (en) Process for the conversion of beclomethasone 17,21-di-propionate the crystals whereof are liable to growth in an aerosol propellent into a from showing no such growth tendency
AU473321B2 (en) Removal of material from bulk storage
CA989388A (en) Extraction of sterolins from plant material
YU226674A (en) Process for obtaining 2-amino-5-alkyl-1,3,4-thiadiazole
ZA732973B (en) Process for preparing 1-(5-alkyl-1,3,4-thiadiazol-2-yl)-1,3-diakyl ureas
IL37881A (en) A process for the production of active 1'-demethyl-lincomycin compounds
YU264480A (en) Process for obtaining the p-biphenylester of 11,15-bis-(tetrahydropyran-5-yloxy)-16-substituted tetranorprostadienic acid
ZA755512B (en) Process for the production of 3-hydroxy-1,2,4-triazole derivatives
EG12168A (en) Process for the manufacture of double nas propellant charges for roeks,ejector charges and the like
IL47053A (en) Process for the preparation of 3-trichloromethyl-5-chloro-1,2,4-thiadiazole
PH9700A (en) A process for the manufacture of 20beta-hydroxy-9-oxo-1,2,3,4,10,19-hexanor-5,9-seco-pregnan-5-oic acid
CA848971A (en) Process for the production of 21-acyloxy-.delta.9(11)-steroids
CA899906A (en) Process for the preparation of 1,2-disubstituted hydrazines
ZA753777B (en) Process for the production of 1,2,4-triazole derivatives
CA929129A (en) Process for the production of 2,6-dicyanotrichloropyridine from a 2,6-dicyanopiperidine compound
JPS51125057A (en) Process for preparing *11oxoo22phenyl* halophenyl or thienyll22mehyll 6*77dichlorooindanyloxy*acetate
CA870595A (en) PROCESS FOR PREPARING 3.beta.-HYDROXY-.DELTA.5(10)-STEROIDS
AU449751B2 (en) Conveyor plant forthe continuous removal of bulk material
CA913596A (en) Acid gas removal from gas mixtures
CA869868A (en) Aerosol product residue eliminator
AU472433B2 (en) A method for the formation of articles from collagenous material
AU2258070A (en) Conveyor plant forthe continuous removal of bulk material
AU474207B2 (en) New 6-keto-1,3,5(10)-steroids and process for the manufacture of 6-keto-1,3,5(10)-steroids
AU478472B2 (en) Agent for the regulation of plant growth
AU485899B2 (en) Agent for the regulation of plant growth